ArriVent BioPharma’s firmonertinib has failed to meet the primary endpoint in the pivotal Phase 3 FURVENT trial evaluating the oral EGFR inhibitor as first-line treatment for advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations. At the 240 mg dose, median progression-free survival by blinded independent central review reached 11.0 months compared with 9.5 months for platinum-based chemotherapy, producing a hazard ratio of 0.75 and a p-value of 0.0654. Although several secondary measures favored firmonertinib and overall survival remains immature, the independently assessed primary analysis did not establish the statistically significant PFS improvement required for a conventionally positive Phase 3 result.
The result creates an uncertain regulatory path for a program that holds FDA Breakthrough Therapy designation in this setting and had been positioned as a potential chemotherapy-free first-line option. ArriVent said it is reviewing the full FURVENT dataset before deciding how to proceed, making the differences between independent and investigator assessments, the response-rate advantage and eventually mature survival data particularly important to the program’s future.
Independent review shows the 240 mg dose fell short despite numerical PFS improvement
FURVENT enrolled 398 patients with previously untreated, locally advanced or metastatic non-squamous NSCLC carrying EGFR exon 20 insertion mutations. The global three-arm study compared once-daily firmonertinib at either 160 mg or 240 mg with platinum-based chemotherapy plus pemetrexed, with progression-free survival assessed by blinded independent central review serving as the primary endpoint.
At 240 mg, median independently assessed PFS was 11.0 months versus 9.5 months with chemotherapy. The hazard ratio of 0.75 corresponded to an estimated 25% reduction in the risk of progression or death, but the 95% confidence interval extended from 0.55 to 1.02 and the p-value of 0.0654 remained above the conventional 0.05 threshold.
The 160 mg dose performed less favorably. Median PFS was 8.4 months, shorter than the 9.5 months observed with chemotherapy, with a hazard ratio of 0.91 and a 95% confidence interval of 0.67 to 1.25. These results reinforce 240 mg as the more active of the two tested doses but do not rescue the study’s primary endpoint.
Objective response provided a more encouraging signal. Confirmed response by blinded independent review reached 60% with 240 mg firmonertinib, compared with 35% at 160 mg and 33% with chemotherapy. The substantial increase in tumor response at the higher dose indicates antitumor activity even though that activity did not translate into a statistically significant improvement in the trial’s primary PFS analysis.
Investigator-assessed PFS creates an important but secondary efficacy discrepancy
A notable feature of FURVENT is the difference between independent central review and investigator assessment. Treating investigators reported median PFS of 11.1 months with 240 mg firmonertinib versus 7.1 months with chemotherapy, corresponding to a hazard ratio of 0.61. Investigator-assessed response rates were similarly favorable at 61% with 240 mg compared with 28% in the control arm.
For the 160 mg dose, investigator-assessed PFS reached 8.3 months compared with 7.1 months for chemotherapy, producing a hazard ratio of 0.86. The greater separation seen with investigator assessment therefore centered primarily on the 240 mg regimen, consistent with the dose-response pattern seen in the independent response-rate analysis.
The discrepancy does not mean one assessment is necessarily incorrect. Radiographic progression can involve judgment around lesion measurement, scan timing and whether equivocal changes meet RECIST criteria, which is why pivotal oncology trials frequently use blinded central review to reduce potential assessment bias. Because BICR was the prespecified primary endpoint in FURVENT, the more favorable investigator analysis is supportive evidence rather than a substitute for the failed primary result.
ArriVent also reported a trend toward improved overall survival, but those data are not yet mature and numerical results were not disclosed. Mature survival follow-up could affect the clinical interpretation of the study, particularly if the 240 mg arm ultimately demonstrates a meaningful survival advantage, but an immature trend cannot currently be used to conclude that firmonertinib extends life.
Safety favored firmonertinib on treatment-related severe adverse events
The safety findings did not identify a new tolerability problem that would explain the efficacy outcome. Grade 3 or higher treatment-emergent adverse events occurred in 52% of patients receiving firmonertinib 240 mg, 53% receiving 160 mg and 55% receiving chemotherapy.
Treatment-related severe events showed a larger difference. Grade 3 or higher treatment-related adverse events occurred in 26% of the 240 mg group and 22% of the 160 mg group compared with 40% of patients receiving the chemotherapy control regimen. ArriVent said the overall safety profile remained consistent with previous studies of firmonertinib and that no new safety signals emerged.
That profile could still be clinically attractive if a viable development path remains because firmonertinib is an oral targeted therapy rather than a platinum-based chemotherapy regimen. However, improved convenience or tolerability alone is unlikely to overcome failure of the pivotal efficacy endpoint when seeking a first-line targeted-therapy approval, particularly when the trial was specifically designed to establish superior disease control.
The eventual benefit-risk assessment will therefore depend on the complete dataset rather than toxicity alone. Duration of response, central nervous system activity and mature overall survival could provide additional context, especially because firmonertinib was designed to penetrate the brain and patients with EGFR-mutant NSCLC frequently develop CNS metastases.
FURVENT miss disrupts a program supported by Breakthrough Therapy designation and Chinese approval
Firmonertinib is a mutation-selective EGFR inhibitor designed to inhibit both common and uncommon EGFR alterations and achieve meaningful central nervous system exposure. The FDA previously granted Breakthrough Therapy designation for untreated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, reflecting encouraging earlier evidence and the unmet need in this molecular subgroup.
EGFR exon 20 insertions account for approximately 9% of EGFR mutations according to ArriVent and historically respond poorly to many conventional EGFR tyrosine kinase inhibitors. Patients have therefore remained a distinct drug-development population despite the substantial progress made for more common exon 19 deletion and L858R-mutant lung cancers.
Firmonertinib already has regulatory validation in China, where ArriVent’s partner Shanghai Allist Pharmaceuticals received approval for patients with EGFR exon 20 insertion-positive locally advanced or metastatic NSCLC whose disease progressed during or after platinum chemotherapy or who could not tolerate platinum treatment. That approval applies to a later-line population and therefore does not resolve the question now raised by FURVENT about first-line use.
The Phase 3 miss makes a straightforward U.S. first-line filing considerably less certain. Breakthrough Therapy designation can facilitate interactions with the FDA and expedite development, but it does not reduce the evidentiary requirement to demonstrate an acceptable benefit-risk profile or convert a statistically negative pivotal trial into an approvable result.
ArriVent has not announced that it will discontinue the exon 20 insertion program. The company instead said it is evaluating the complete FURVENT dataset to determine the appropriate development path, leaving open possibilities that could include additional analyses, regulatory discussions or a narrower future strategy.
Failure in exon 20 insertion disease does not automatically invalidate firmonertinib’s PACC program
Firmonertinib is also being developed in another group of uncommon EGFR mutations known as P-loop and alpha-C-helix compressing, or PACC, mutations. ArriVent is running the global Phase 3 ALPACCA trial in previously untreated PACC-mutant NSCLC, making it important to distinguish that program from FURVENT rather than assume the exon 20 insertion outcome predicts the same result.
Earlier Phase 1b data in first-line PACC-mutant disease showed median PFS of 16.0 months with 240 mg firmonertinib, a confirmed objective response rate of 68.2% and a median response duration of 14.6 months by blinded independent review. Central nervous system responses were also reported, including complete intracranial responses in several evaluable patients.
Those results come from a smaller proof-of-concept dataset and cannot guarantee Phase 3 success, but they involve a biologically different mutation group. ALPACCA therefore remains an independent test of whether firmonertinib’s broad EGFR profile can deliver clinically meaningful benefit in another uncommon EGFR-defined population.
ArriVent also has a developing antibody-drug conjugate pipeline that reduces, but does not eliminate, its dependence on firmonertinib. ARR-217 has moved into Phase 1b dose optimization in gastrointestinal cancers, while ARR-002 is entering clinical development in ovarian and endometrial cancers. The company reported $373.1 million in cash and investments at the end of the second quarter and expected its resources to support operations into 2028.
The immediate scientific focus remains FURVENT. A 60% response rate and investigator-assessed PFS benefit indicate that 240 mg firmonertinib is pharmacologically active in exon 20 insertion-positive disease, but the independent-review primary endpoint is the outcome on which the pivotal trial was designed to succeed.
The next meaningful update will require more than emphasizing favorable secondary endpoints. Mature overall survival, detailed duration-of-response and CNS data, and discussions with regulators will determine whether FURVENT leaves any viable first-line path for firmonertinib or whether ArriVent’s development strategy increasingly shifts toward PACC-mutant lung cancer and its newer oncology assets.
